Hi Bava, I do enjoy your thread. I know B Cell have been disprioritised for other 3 platforms with clinic trials. While we do expect a license out for HER-vaxx which was on previous presentation that business development discussion are undergoing for HER-Vaxx. if they put value of B cell as zero right now, the current SP makes sense at all phase 1 trial without significant data yet announced. All are speculations from here.
Ann: Imugene Corporate Presentation, page-41
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |